Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT02668770	TitleIpilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies	Phase Phase 1	Date Added 2016-01-29	Location Texas, United States	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs Ipilimumab, MGN1703	Tags MSS/ MMRp
NCT ID NCT02617277	TitleSafety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours	Phase Phase 1	Date Added 2015-11-30	Location Colorado, United States Florida, United States Tennessee, United States	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs AZD1775, MEDI4736	Tags MSS/ MMRp
NCT ID NCT02608385	TitleStudy of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors	Phase Phase 1	Date Added 2015-11-18	Location Illinois, United States	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs Pembrolizumab	Tags MSS/ MMRp
NCT ID VAPER	TitleA study looking at using a vaccine and chemotherapy to treat advanced cancer	Phase Phase 1	Date Added 2015-11-17	Location	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs Celecoxib, Cyclophosphamide, imiquimod, vaccine	Tags MSS/ MMRp
NCT ID NCT02600949	TitlePersonalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer	Phase Phase 1	Date Added 2015-11-09	Location Texas, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs imiquimod, Pembrolizumab, Sotigalimab, Synthetic Tumor-Associated Peptide Vaccine Therapy	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT02537418	TitleDurvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens	Phase Phase 1	Date Added 2015-09-01	Location Canada	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs durvalumab, Tremelimumab, Imfinzi	Tags MSS/ MMRp
NCT ID NCT02499328	TitleStudy to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck	Phase Phase 1, Phase 2	Date Added 2015-07-16	Location Alabama, United States California, United States Colorado, United States Florida, United States Indiana, United States Massachusetts, United States Michigan, United States Montana, United States New Jersey, United States Ohio, United States Texas, United States Virginia, United States Washington, United States Belgium Germany Italy Spain United Kingdom	Prior IO Allowed No	CRC-directed No	Status Active, not recruiting	Drugs AZD5069, AZD9150, MEDI4736, tremelimumab (treme)	Tags MSS/ MMRp
NCT ID NCT02484404	TitlePhase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can…	Phase Phase 1, Phase 2	Date Added 2015-06-29	Location Maryland, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Cediranib, durvalumab, Olaparib	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT02465060	TitleTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Phase Phase 2	Date Added 2015-06-08	Location Alabama, United States Alaska, United States Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States Guam Puerto Rico	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Adavosertib, afatinib, Afatinib Dimaleate, Binimetinib, Capivasertib, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Larotrectinib Sulfate, Nivolumab, Osimertinib, palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab emtansine, Ulixertinib, Vismodegib	Tags MSS/ MMRp
NCT ID NCT02453620	TitleEntinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer	Phase Phase 1	Date Added 2015-05-25	Location California, United States Connecticut, United States Maryland, United States Pennsylvania, United States	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs Entinostat, Ipilimumab, Nivolumab, Opdivo, Yervoy	Tags MSS/ MMRp

Showing 281 to 290 of 299 entries